Skip to main content
SNYR
NASDAQ Life Sciences

Registers Resale of 101.7M Shares for $36M Equity Line, Signaling Massive Dilution

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
9
Price
$0.282
Mkt Cap
$4.272M
52W Low
$0.27
52W High
$4
Market data snapshot near publication time

summarizeSummary

Synergy CHC Corp. registered 101.7 million shares for resale, primarily tied to a $36 million equity line of credit, indicating a potential dilution of over 681% for existing shareholders amidst ongoing financial distress.


check_boxKey Events

  • Registration of 101.7 Million Shares for Resale

    The company filed an S-1 to register 101,710,000 shares of common stock for resale by Hudson Global Ventures, LLC. These shares include 100,000,000 ELOC Shares, 1,540,000 Warrant Shares, and 170,000 Existing Shares.

  • Equity Line of Credit (ELOC) Details

    The registered shares are primarily associated with a $36 million Equity Line of Credit (ELOC) established on May 8, 2026. The company has the right, but not the obligation, to sell shares to the Selling Stockholder at a discounted market price to draw funds.

  • Extreme Potential Dilution

    If all 101,540,000 new shares (ELOC and Warrant Shares) are issued, it would represent a dilution of approximately 681% of the 14,899,883 shares outstanding as of May 14, 2026. This is a highly dilutive offering.

  • Shareholder Approval for Issuance Cap

    The company requires shareholder approval to issue shares exceeding 19.99% of its outstanding common stock under the ELOC Purchase Agreement. A recent PRE 14A filing indicated the company is seeking approval for a highly dilutive equity plan expansion.


auto_awesomeAnalysis

Synergy CHC Corp. has filed an S-1 registration statement for the resale of up to 101,710,000 shares of common stock by Hudson Global Ventures, LLC. These shares are primarily linked to a previously announced $36 million Equity Line of Credit (ELOC) and associated warrants. While the company will not receive proceeds from the resale, it may draw up to $36 million from the ELOC by issuing shares at a discounted market price. This registration, following the recent announcement of the ELOC, formalizes the potential for extreme dilution. If all shares registered for resale are issued, it represents a potential dilution of over 681% of the company's currently outstanding shares. This substantial capital raise, at discounted prices and near 52-week lows, is critical for the company's liquidity given its recent history of significant net losses, material weaknesses, and a mandatory equity raise condition on its term loan. The company is also seeking shareholder approval to issue shares beyond a 19.99% cap, indicating an intent to fully utilize this highly dilutive financing mechanism.

At the time of this filing, SNYR was trading at $0.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $0.27 to $4.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed SNYR - Latest Insights

SNYR
May 15, 2026, 5:07 PM EDT
Filing Type: S-1
Importance Score:
9
SNYR
May 14, 2026, 8:19 AM EDT
Filing Type: 10-Q
Importance Score:
9
SNYR
May 11, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
SNYR
Apr 17, 2026, 4:16 PM EDT
Filing Type: PRE 14A
Importance Score:
9
SNYR
Apr 01, 2026, 6:15 AM EDT
Source: Wiseek News
Importance Score:
9
SNYR
Mar 31, 2026, 9:23 PM EDT
Filing Type: 10-K
Importance Score:
9
SNYR
Mar 25, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
9
SNYR
Mar 25, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
9
SNYR
Mar 03, 2026, 5:23 PM EST
Source: Wiseek News
Importance Score:
8
SNYR
Mar 03, 2026, 5:20 PM EST
Filing Type: 8-K
Importance Score:
8